Premier Stocks League

2 Healthcare Stocks That Just Delivered Great News for Investors 🔗

And there could be more positive developments ahead.

Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now? 🔗

Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering t...

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know 🔗

Vertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day.

Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing 🔗

Will Vertex's Kidney Disease Pipeline Be a New Growth Engine? 🔗

VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.

Lilly’s latest China drug deal; Immunovant’s setback in lupus 🔗

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Ve...

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? 🔗

One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly...

Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues 🔗

Vertex Pharmaceuticals has ridden a powerful five year share price run while pushing deeper into kidney disease, endocrinology and pain treatments, wh...

Vertex Posts Positive Phase II Data on Kidney Disease Drug 🔗

VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.

Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage 🔗

Maze Therapeutics (NASDAQ:MAZE) shares rose 2. 9% in pre-market trading after CIBC initiated coverage of the clinical-stage biopharmaceutical company ...

CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon 🔗

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst see...

Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race 🔗

Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals an...

The Surprise That Sent Vertex — And Its Chief Rival — Soaring 🔗

Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.

Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder 🔗

Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney...

Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech 🔗

Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maz...

SBIO: Big Pharma Needs What This Fund Owns 🔗

The ALPS Medical Breakthroughs ETF is a Buy, as its pullback offers a better entry into late-stage biotech. Click for more on the SBIO ETF.

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know 🔗

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug 🔗

Vertex Pharmaceuticals reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease.

Chronic Kidney Disease (CKD) Market Gains Momentum as Pipeline Innovation and Clinical Trials Reshape the Competitive Landscape in 2026 🔗

CKD drug development is shifting toward disease-modifying and cardiorenal therapies, creating opportunities in early detection, high-risk screening, c...

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It 🔗

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial 🔗

BOSTON, September 22, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of i...